Gerald Brock1, Darell Heiselman2, Mario Maggi3, Sae Woong Kim4, José M Rodríguez Vallejo5, Hermann M Behre6, John McGettigan7, Sherie A Dowsett2, Risa P Hayes2, Jack Knorr2, Xiao Ni2, Kraig Kinchen2. 1. Department of Surgery, University of Western Ontario, London, Ontario, Canada. Electronic address: gebrock@sympatico.ca. 2. Eli Lilly and Co., Indianapolis, Indiana. 3. Department of Clinical Physiopathology, University of Florence, Florence, Italy. 4. Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Korea. 5. Urology Service, Hospital Infanta Leonor, Madrid, Spain. 6. Center for Reproductive Medicine and Andrology, University Hospital Halle (Saale), Halle, Germany. 7. Quality of Life Medical and Research Center, Tucson, Arizona.
Abstract
PURPOSE: We determined the effect of testosterone solution 2% on total testosterone level and the 2 symptoms of hypogonadism, sex drive and energy level. MATERIALS AND METHODS: This was a randomized, multicenter, double-blind, placebo controlled, 16-week study to compare the effect of testosterone and placebo on the proportion of men with a testosterone level within the normal range (300 to 1,050 ng/dl) upon treatment completion. We also assessed the impact of testosterone on sex drive and energy level measured using SAID (Sexual Arousal, Interest and Drive scale) and HED (Hypogonadism Energy Diary), respectively. A total of 715 males 18 years old or older with total testosterone less than 300 ng/dl and at least 1 symptom of testosterone deficiency (decreased energy and/or decreased sexual drive) were randomized to 60 mg topical testosterone solution 2% or placebo once daily. RESULTS: Of study completers 73% in the testosterone vs 15% in the placebo group had a testosterone level within the normal range at study end point (p <0.001). Participants assigned to testosterone showed greater baseline to end point improvement in SAID scores (low sex drive subset p <0.001 vs placebo) and HED scores (low energy subset p = 0.02 vs placebo, not significant at prespecified p <0.01). No major adverse cardiovascular or venous thrombotic events were reported in the testosterone group. The incidence of increased hematocrit was higher with testosterone vs placebo (p = 0.04). CONCLUSIONS: Once daily testosterone solution 2% for 12 weeks was efficacious in restoring normal testosterone levels and improving sexual drive in hypogonadal men. Improvement was also seen in energy levels on HED though not at the prespecified p <0.01. No new safety signals were identified.
RCT Entities:
PURPOSE: We determined the effect of testosterone solution 2% on total testosterone level and the 2 symptoms of hypogonadism, sex drive and energy level. MATERIALS AND METHODS: This was a randomized, multicenter, double-blind, placebo controlled, 16-week study to compare the effect of testosterone and placebo on the proportion of men with a testosterone level within the normal range (300 to 1,050 ng/dl) upon treatment completion. We also assessed the impact of testosterone on sex drive and energy level measured using SAID (Sexual Arousal, Interest and Drive scale) and HED (Hypogonadism Energy Diary), respectively. A total of 715 males 18 years old or older with total testosterone less than 300 ng/dl and at least 1 symptom of testosterone deficiency (decreased energy and/or decreased sexual drive) were randomized to 60 mg topical testosterone solution 2% or placebo once daily. RESULTS: Of study completers 73% in the testosterone vs 15% in the placebo group had a testosterone level within the normal range at study end point (p <0.001). Participants assigned to testosterone showed greater baseline to end point improvement in SAID scores (low sex drive subset p <0.001 vs placebo) and HED scores (low energy subset p = 0.02 vs placebo, not significant at prespecified p <0.01). No major adverse cardiovascular or venous thrombotic events were reported in the testosterone group. The incidence of increased hematocrit was higher with testosterone vs placebo (p = 0.04). CONCLUSIONS: Once daily testosterone solution 2% for 12 weeks was efficacious in restoring normal testosterone levels and improving sexual drive in hypogonadal men. Improvement was also seen in energy levels on HED though not at the prespecified p <0.01. No new safety signals were identified.
Authors: Glenn R Cunningham; Alisa J Stephens-Shields; Raymond C Rosen; Christina Wang; Shalender Bhasin; Alvin M Matsumoto; J Kellogg Parsons; Thomas M Gill; Mark E Molitch; John T Farrar; David Cella; Elizabeth Barrett-Connor; Jane A Cauley; Denise Cifelli; Jill P Crandall; Kristine E Ensrud; Laura Gallagher; Bret Zeldow; Cora E Lewis; Marco Pahor; Ronald S Swerdloff; Xiaoling Hou; Stephen Anton; Shehzad Basaria; Susan J Diem; Vafa Tabatabaie; Susan S Ellenberg; Peter J Snyder Journal: J Clin Endocrinol Metab Date: 2016-06-29 Impact factor: 5.958
Authors: Andrea Salonia; Giulia Rastrelli; Geoffrey Hackett; Stephanie B Seminara; Ilpo T Huhtaniemi; Rodolfo A Rey; Wayne J G Hellstrom; Mark R Palmert; Giovanni Corona; Gert R Dohle; Mohit Khera; Yee-Ming Chan; Mario Maggi Journal: Nat Rev Dis Primers Date: 2019-05-30 Impact factor: 52.329
Authors: Peter J Snyder; Shalender Bhasin; Glenn R Cunningham; Alvin M Matsumoto; Alisa J Stephens-Shields; Jane A Cauley; Thomas M Gill; Elizabeth Barrett-Connor; Ronald S Swerdloff; Christina Wang; Kristine E Ensrud; Cora E Lewis; John T Farrar; David Cella; Raymond C Rosen; Marco Pahor; Jill P Crandall; Mark E Molitch; Susan M Resnick; Matthew Budoff; Emile R Mohler; Nanette K Wenger; Harvey Jay Cohen; Stanley Schrier; Tony M Keaveny; David Kopperdahl; David Lee; Denise Cifelli; Susan S Ellenberg Journal: Endocr Rev Date: 2018-06-01 Impact factor: 19.871
Authors: Glenn R Cunningham; Susan S Ellenberg; Shalender Bhasin; Alvin M Matsumoto; J Kellogg Parsons; Peter Preston; Jane A Cauley; Thomas M Gill; Ronald S Swerdloff; Christina Wang; Kristine E Ensrud; Cora E Lewis; Marco Pahor; Jill P Crandall; Mark E Molitch; Denise Cifelli; Shehzad Basaria; Susan J Diem; Alisa J Stephens-Shields; Xiaoling Hou; Peter J Snyder Journal: J Clin Endocrinol Metab Date: 2019-12-01 Impact factor: 5.958
Authors: Christina Wang; Alisa J Stephens-Shields; Leonard R DeRogatis; Glenn R Cunningham; Ronald S Swerdloff; Peter Preston; David Cella; Peter J Snyder; Thomas M Gill; Shalender Bhasin; Alvin M Matsumoto; Raymond C Rosen Journal: J Sex Med Date: 2018-07 Impact factor: 3.802
Authors: Karol M Pencina; Arthur L Burnett; Thomas W Storer; Wen Guo; Zhuoying Li; Adam S Kibel; Grace Huang; Michelle Blouin; Donna L Berry; Shehzad Basaria; Shalender Bhasin Journal: J Clin Endocrinol Metab Date: 2021-07-13 Impact factor: 5.958